#mariposa2 search results

3/3 #FLAURA #MARIPOSA2 #lungcancer #egfr #nsclc #LCSM 🫁 Study design 🫁

Great point!! Agree. Not all mutations are the same. Data from #ASCO25 regarding #MARIPOSA2 suggests it is a strong option regardless of baseline osi resistance mechanism.

As combination strategies move to the frontline for our patients, how do we integrate the #MARIPOSA2 regimen in our practice? @BalazsHalmosMD @OncBrothers @jillfeldman4

Getting great questions from patients with EGFR+ lung cancer about the #MARIPOSA and #MARIPOSA2 studies after #ELCC25, and how they differ. What else should we add to this table to make it more helpful? @EGFRResisters @jillfeldman4

Updated @ASCO living guideline for Stage4 #NSCLC ŵ driver mutation Incorporates findings of #MARIPOSA and #MARIPOSA2: recommends consideration of Amivantamab in 1° and 2° #EGFR ex19 or L858R settings. Both studies improved PFS, OS immature ascopubs.org/doi/pdf/10.120…

Sequencing therapies for patients is so important! As of 9/2024–Amivantamab plus chemotherapy has FDA approval after progression on oral osimertinib per #MARIPOSA2.

The FDA approved #amivantamab with carboplatin & pemetrexed for adults with advanced #NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations after prior EGFR TKI therapy. #MARIPOSA2 showed improved PFS vs. chemo alone (HR 0.48, P<0.0001). bit.ly/4evELjl

The FDA approved #amivantamab with carboplatin & pemetrexed for adults with advanced #NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations after prior EGFR TKI therapy. #MARIPOSA2 showed improved PFS vs. chemo alone (HR 0.48, P<0.0001). bit.ly/4evELjl

#Amivantamab + Chemo now @US_FDA approved in 2L mEGFR NSCLC after Osimertinib based off #MARIPOSA2: - mOS 17.7mos w/ Ami vs 15.3mos with chemo alone (HR 0.73), but ‘did NOT reach pre-specified significance’ - mPFS2 16mos vs 11.6mos (HR: 0.64) #ESMO24 #OncTwitter #lcsm

1. #MARIPOSA2: Update, Ph III, 2L in mEGFR after Osimertinib, Amivantamab + Chemo vs Chemo: - Recently approved in Europe - mOS 17.7mos w/ Ami vs 15.3mos with chemo alone (HR 0.73), but ‘did NOT reach pre-specified significance’ - mPFS2 16mos vs 11.6mos (HR: 0.64) 2/9

And my favourite slide from #MARIPOSA2 study: huge heterogeneity of post-PD treatments in 3rd line. This underlines the vast heterogeneity of the disease and the need for options. #ESMO2024

@Rajatraj we have some data on that based off #MARIPOSA2 (Ami + Chemo or Ami + Laz + Chemo after upfront TKI). There is higher RR + PFS with Ami + Chemo +/- Laz vs Chemo. In most pts with progressive disease on Osi, I’ll likely add chemo and cont Osi or switch to Ami + Chemo.

L'amivantamab est disponible en accès précoce preAMM en deuxième ligne après échec d'un TKI et en association au carbo-pemetrexed, dans les mutations standards de l'EGFR. Une vraie avancée pour nos patients ! @HAS_sante @ansm @JanssenCilag #MARIPOSA2.

3/3 #FLAURA #MARIPOSA2 #lungcancer #egfr #nsclc #LCSM 🫁 Study design 🫁

Hasil war 🔥🔥🔥 #MARIPOSA2 #luluk

#ESMO23 💥 LAST Presidential3 @myESMO #MARIPOSA2 Amivantamab+Lazertinib+CT vs Amivantamab+CT vs CT #EGFRmut #NSCLC 📌 PFS 8.3 vs 6.3 vs 4.2m HR 0.48/0.44 📌 OS NS 📌 ORR 63 vs 64 vs 36% (OR 3.1) ☣️>G3 92% vs72% vs48% @ASCO @myESMO @_SEOM @OncoAlert @OncBrothers @weoncologists

Getting great questions from patients with EGFR+ lung cancer about the #MARIPOSA and #MARIPOSA2 studies after #ELCC25, and how they differ. What else should we add to this table to make it more helpful? @EGFRResisters @jillfeldman4

Barbie Mariposa & the Fairy Princess #Mariposa2

Cuma iqbal jadi bucin aja bangga 😂 #Mariposa2 #wattpad

Iqbal baik-baik di Paris ya🙂 #mariposa2 #lulukhf

6. #MARIPOSA2: Amivantamab + Laz + Chemo Vs Chemo Vs Ami + Chemo in 2L activating EGFR mNSCLC after Osi. - Improved PFS with Ami combo: 8.3mos (Ami/Laz/Chemo), 6.3mos (Ami/Chemo), 4.2mos (HR: 0.44 and 0.42) - Improved CNS PFS - Significant AEs with combo @APassaroMD 7/7

#ESMO23 1> #lungcancer 1-15> (LBA15) Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: #MARIPOSA2, a Phase 3, Global, Randomized, Controlled Trial. #Osimertinib-resistant EGFR-mutant…

And my favourite slide from #MARIPOSA2 study: huge heterogeneity of post-PD treatments in 3rd line. This underlines the vast heterogeneity of the disease and the need for options. #ESMO2024

#Amivantamab + Chemo now @US_FDA approved in 2L mEGFR NSCLC after Osimertinib based off #MARIPOSA2: - mOS 17.7mos w/ Ami vs 15.3mos with chemo alone (HR 0.73), but ‘did NOT reach pre-specified significance’ - mPFS2 16mos vs 11.6mos (HR: 0.64) #ESMO24 #OncTwitter #lcsm

#MARIPOSA2

@Rajatraj we have some data on that based off #MARIPOSA2 (Ami + Chemo or Ami + Laz + Chemo after upfront TKI). There is higher RR + PFS with Ami + Chemo +/- Laz vs Chemo. In most pts with progressive disease on Osi, I’ll likely add chemo and cont Osi or switch to Ami + Chemo.

🔥🚨@OncoAlert Hot off the press Just published @Annals_Oncology in conjunction with presentation @myESMO #ESMO23 Results of #MARIPOSA2 trial of #Amivantamab +chemo with & without #Lazertinib in #EGFR+ advanced #NSCLC post progression on #Osimertinib 👇🏼 annalsofoncology.org/article/S0923-…

Waduh sama sama 30k nihh #TIMIQBALACHA #MARIPOSA2

Outstanding plenary presentation of the #MARIPOSA2 phase 3 trial by @APassaroMD, demonstrating the benefit of amivantamab/chemo (with or without lazertinib) over chemo in osi-refractory patients with EGFR-mutant NSCLC. #ESMO23

1. #MARIPOSA2: Update, Ph III, 2L in mEGFR after Osimertinib, Amivantamab + Chemo vs Chemo: - Recently approved in Europe - mOS 17.7mos w/ Ami vs 15.3mos with chemo alone (HR 0.73), but ‘did NOT reach pre-specified significance’ - mPFS2 16mos vs 11.6mos (HR: 0.64) 2/9

Nih ade nya dilan sebelas dua belas sama kakanya, mainannya ngilang #mariposa2

UDAH BACA MARIPOSA 1 dari kak @lulukhf_stories ?? Kalo udah, Siap2 ikutan PO #Mariposa2 yaa.... Yang belum follow, follow dulu yak supaya ga ketinggalan info promo. Dan yang blm punya #Mariposa 1 bisa order di BukuWanita 😍😍 @coconutbooks_

oiya dari kemaren mau aploud ini lupa terus hihihi #mariposa2 @luluk_hf